AstraZeneca PLC

NYSE:AZN

Drug Manufacturers - General

Healthcare
$178.76 -1.71%

-$3.04 today

Market cap
$277.23B
Beta
0.21
P/E (TTM)
25.7
EPS (TTM)
$6.75
Dividend yield
1.80%
52W Low $137.22High $212.71

Volume 2.54M

Average 1.96M

AZN Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

AstraZeneca PLCNYSE: AZN

Gross Margin · Q3 FY2026 · quarter ended Sep 2026

Gross margin narrows to 74.6%

Gross margin was 74.6% in Q3 FY2026, down 6.9 pp from a year earlier. On a trailing-twelve-month basis it was 80.1%, down 2.3 pp year over year. Over 3 fiscal years it widened by 9.8 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
74.6%-9.0 pp QoQ
Last fiscal yearDec 2025
81.9%+0.8 pp YoY
LTMSep 2026
80.1%-2.3 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-6.9 pp——
1 year+0.8 pp——
3 years+9.8 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
81.9%
Year-over-year change
+0.8pp

Gross Margin vs competitors

How AZN compares with its peers on the latest reported figures

  • AZN's LTM Sep 2026 gross margin of 80.1% is the 3rd highest of the 10 companies compared; the peer median is 74.4%.
  • Its year-over-year change of -2.3 pp is the 9th highest of 10, against a peer median of +0.7 pp.
  • Over three fiscal years its change of +9.8 pp compares with a peer median of +0.2 pp.
AZN Competitors Peer median
Gross Margin for AZN and competitors
Company Period LTM level YoY 3-year change
LLYEli Lilly and CompanyLTM Jun 202683.4% +0.8 pp+6.3 pp
NVONovo Nordisk A/SLTM Jun 202680.6% -3.3 pp-2.9 pp
AZNAstraZeneca PLCLTM Sep 202680.1% -2.3 pp+9.8 pp
ABBVAbbVie Inc.LTM Sep 202676.3% +6.5 pp+0.2 pp
MRKMerck & Co., Inc.LTM Jun 202675.4% -0.1 pp+1.3 pp
NVSNovartis AGLTM Jun 202674.4% -1.8 pp+1.7 pp
PFEPfizer Inc.LTM Jun 202673.2% +1.1 pp+8.3 pp
AMGNAmgen Inc.LTM Jun 202672.7% +8.2 pp-4.9 pp
BMYBristol-Myers Squibb CompanyLTM Jun 202670.2% -0.1 pp-7.0 pp
JNJJohnson & JohnsonLTM Sep 202668.8% +0.7 pp-1.4 pp
Peer median (excluding AZN) 74.4%+0.7 pp+0.2 pp

Competitors are the stored peer set for AZN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue37.42B44.35B45.81B54.07B58.74B
Cost of Revenue12.44B12.39B8.27B10.21B10.63B
Gross Profit24.98B31.96B37.54B43.87B48.11B
Gross Margin66.8%72.1%82.0%81.1%81.9%
Research & Development9.74B9.76B10.94B13.58B14.23B
Selling, General & Admin15.59B17.98B18.22B20.22B20.51B
Operating Expenses23.92B28.2B29.35B33.86B34.36B
Depreciation & Amortization4.1B5.25B4.93B5.07B5.73B
EBITDA5.11B9.09B13.42B15.44B19.83B
EBITDA Margin13.7%20.5%29.3%28.6%33.8%
Operating Income1.06B3.76B8.19B10B13.74B
Operating Margin2.8%8.5%17.9%18.5%23.4%
Interest Income43M81M301M345M360M
Interest Expense1.28B1.33B1.59B1.68B1.69B
Other Income / Expenses(1.32B)(1.26B)(1.29B)(1.31B)(1.34B)
Income Before Tax(265M)2.5B6.9B8.69B12.4B
Pre-Tax Margin-0.7%5.6%15.1%16.1%21.1%
Income Tax Expense(380M)(792M)938M1.65B2.17B
Net Income112M3.29B5.96B7.04B10.26B
Net Margin0.3%7.4%13.0%13.0%17.5%
EPS (Basic)0.082.123.814.546.60
EPS (Diluted)0.082.113.814.506.54
Weighted Avg Shares1.42B1.55B1.56B1.55B1.55B
Weighted Avg Shares (Diluted)1.43B1.56B1.56B1.56B1.56B

AstraZeneca PLC

NYSE:AZN

Intrinsic Alpha fair value

Locked

Current Price

$178.76

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.